tetano
Editor, Senior Moderator
J Microbiol
. 2026 Feb;64(2):e2510016.
doi: 10.71150/jm.2510016. Epub 2026 Feb 28.
Armored RNA technology as a clinical diagnostics tool for future pandemic preparedness
Jin Hao Tan[SUP] 1 [/SUP], Prashant Mainali[SUP] 1 [/SUP], Wei Zhang[SUP] 2 [/SUP], Dave Siak-Wei Ow[SUP] 1 [/SUP]
Affiliations
The COVID-19 pandemic highlighted the critical role of reliable molecular diagnostics in outbreak response and the vulnerabilities of existing systems to delays and reagent instability. Armored RNA technology, which packages RNA within bacteriophage-derived capsids, offers a robust solution by combining nuclease resistance, safety, and versatility into a single platform. Armored RNA has become a trusted internal and external control for RT-qPCR and RT-LAMP, enabling accurate detection across a wide range of viral pathogens. Also, recent advances in alternative expression systems, such as plant-based and cell-free platforms, as well as the use of more stable scaffolds from bacteriophage Qβ, are enhancing yield, stability, and accessibility of armored RNA. Engineering innovations, including capsid polymorphism and optimized downstream purification, further improve efficiency and broaden possible applications. Looking ahead, armored RNA holds promise not only as a diagnostic standard but also as a delivery vehicle for vaccines and therapeutics. Encapsulation of self-amplifying RNA, small interfering RNA, or microRNA could open new pathways for rapid-response vaccines and targeted therapies, aligning this technology with the future of precision medicine. By uniting stability, scalability, and adaptability, armored RNA represents a critical component of global health preparedness, with the potential to strengthen diagnostic resilience and accelerate biomedical countermeasures in future pandemics.
Keywords: E. coli expression; MS2 bacteriophage; RT-PCR; armored RNA; pandemic preparedness.
. 2026 Feb;64(2):e2510016.
doi: 10.71150/jm.2510016. Epub 2026 Feb 28.
Armored RNA technology as a clinical diagnostics tool for future pandemic preparedness
Jin Hao Tan[SUP] 1 [/SUP], Prashant Mainali[SUP] 1 [/SUP], Wei Zhang[SUP] 2 [/SUP], Dave Siak-Wei Ow[SUP] 1 [/SUP]
Affiliations
- PMID: 41802806
- DOI: 10.71150/jm.2510016
The COVID-19 pandemic highlighted the critical role of reliable molecular diagnostics in outbreak response and the vulnerabilities of existing systems to delays and reagent instability. Armored RNA technology, which packages RNA within bacteriophage-derived capsids, offers a robust solution by combining nuclease resistance, safety, and versatility into a single platform. Armored RNA has become a trusted internal and external control for RT-qPCR and RT-LAMP, enabling accurate detection across a wide range of viral pathogens. Also, recent advances in alternative expression systems, such as plant-based and cell-free platforms, as well as the use of more stable scaffolds from bacteriophage Qβ, are enhancing yield, stability, and accessibility of armored RNA. Engineering innovations, including capsid polymorphism and optimized downstream purification, further improve efficiency and broaden possible applications. Looking ahead, armored RNA holds promise not only as a diagnostic standard but also as a delivery vehicle for vaccines and therapeutics. Encapsulation of self-amplifying RNA, small interfering RNA, or microRNA could open new pathways for rapid-response vaccines and targeted therapies, aligning this technology with the future of precision medicine. By uniting stability, scalability, and adaptability, armored RNA represents a critical component of global health preparedness, with the potential to strengthen diagnostic resilience and accelerate biomedical countermeasures in future pandemics.
Keywords: E. coli expression; MS2 bacteriophage; RT-PCR; armored RNA; pandemic preparedness.